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Osteoarthritis (OA) is characterized by the progressive destruction of articular cartilage, which is involved in the imbalance between
extracellular matrix (ECM) synthesis and degradation. MicroRNA-140-5p (miR-140) is speciﬁcally expressed in cartilage and plays
an important role in OA-induced matrix degradation. The aim of this study was to investigate (1) whether intra-articular injection
of melatonin could ameliorate surgically induced OA in mice and (2) whether melatonin could regulate matrix-degrading enzymes
at the posttranscriptional level by targeting miR-140. In an in vitro OA environment induced by interleukin-1 beta (IL-1β),
melatonin treatment improved cell proliferation of human chondrocytes, promoted the expression of cartilage ECM proteins
(e.g., type II collagen and aggrecan), and inhibited the levels of IL-1β-induced proteinases, such as matrix metalloproteinase 9
(MMP9), MMP13, ADAMTS4 (a disintegrin and metalloproteinase with thrombospondin motifs 4), and ADAMTS5. Both the
microarray and polymerase chain reaction (PCR) experiments revealed that miR-140 was a melatonin-responsive microRNA
and melatonin upregulated miR-140 expression, which was suppressed by IL-1β stimulation. In vivo experiments demonstrated
that intra-articular injection of melatonin prevented disruptions of cartilage matrix homeostasis and successfully alleviated the
progression of surgery-induced OA in mice. Transfection of miR-140 antagomir completely counteracted the antiarthritic eﬀects
of melatonin by promoting matrix destruction. Our ﬁndings demonstrate that melatonin protects the articular cartilage from
OA-induced degradation by targeting miR-140, and intra-articular administration of melatonin may beneﬁt patients suﬀering
from OA.

1. Introduction
Osteoarthritis (OA) is a chronic degenerative joint disease,
which is primarily characterized by progressive destruction
of articular cartilage. In the late stages of this pathology,
OA-induced joint dysfunction is considered to be a leading
cause of disability in elderly people, which creates a huge
economic burden on society. Currently, no therapy has been
shown to eﬀectively halt the progression of OA, and the only
clinical treatment for patients with late-stage OA is pros-

thetic implants [1]. Although the pathogenesis of OA is not
yet fully understood, a key factor is the imbalance between
extracellular matrix (ECM) synthesis and degradation in
cartilage [2]. Chondrocytes, the only cell type in articular
cartilage, produce the structural components of the cartilage
ECM, speciﬁcally, type II collagen (Collagen II) and the
proteoglycan aggrecan. However, during OA pathogenesis,
chondrocytes become metabolically active to produce
matrix-degrading enzymes; these enzymes include members
of the matrix metalloproteinase (MMP) and ADAMTS
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(a disintegrin metalloproteinase with thrombospondin
motifs) families, which are responsible for the degradation
of Collagen II and aggrecan, respectively [3]. Among these
enzymes, MMP13 (collagenase-3) can cleave collagen, aggrecan, and ﬁbronectin and has the highest activity toward Collagen II [4]. ADAMTS4 (aggrecanase-1) and ADAMTS5
(aggrecanase-2) have also been shown to play important
roles in OA development [5].
Several recent studies have demonstrated that the gene
expression of matrix-degrading enzymes is tightly regulated
by microRNAs (miRNAs) at the posttranscriptional level
[6]. miRNAs are a class of small (19-24 nucleotides in
length), noncoding RNAs that can regulate gene expression
by binding to speciﬁc sequences in messenger RNAs
(mRNAs), resulting in either degradation of the target
mRNAs or repression of their translation [7]. The diﬀerential
expression of miRNAs between normal and OA cartilage has
been identiﬁed recently using miRNA microarrays [8].
Among them, microRNA-140-5p (miR-140), which is
expressed speciﬁcally in cartilage, has been considered a key
factor in chondrocyte diﬀerentiation and OA-induced matrix
degradation. Deﬁciency of miR-140 in mice resulted in
age-related OA-like changes in cartilage, such as the loss
of proteoglycan and ﬁbrillation of articular cartilage [9].
Additionally, miR-140 is dysregulated by increased levels
of proinﬂammatory cytokines in OA cartilage, such as
interleukin-1 beta (IL-1β) and tumor necrosis factor alpha
(TNF-α). The expression of miR-140 rapidly decreased in
IL-1β-stimulated chondrocytes, suggesting that miR-140
might be implicated in OA cartilage dyshomeostasis [10].
Therefore, miRNA therapeutics, especially regarding strategies targeting miR-140, is a promising treatment option for
OA patients.
Melatonin, a hormone secreted mainly from the pineal
gland, has been shown to exert beneﬁcial eﬀects on bone
diseases, such as osteoporosis, osteopenia, and periodontal
disease [11]. Previous studies from our laboratory and other
groups have demonstrated that melatonin can enhance the
chondrogenic diﬀerentiation of mesenchymal stem cells
(MSCs), even in a proinﬂammatory cytokine-induced
environment [12, 13]. Recently, a study suggested that the
underlying mechanisms involved in melatonin-improved
chondrogenesis was through the upregulation of miRNAs,
such as miR-526b-3p and miR-590-5p, which activated the
Smad signaling pathway by targeting SMAD7, a negative regulator [14]. However, it is unknown whether melatonin can
protect articular cartilage from OA-induced matrix degradation, and few investigations have revealed the role of melatonin in regulating miR-140 during OA pathogenesis.
In this study, we investigated the protective eﬀects of melatonin on OA-impaired articular cartilage. To establish an
in vitro OA environment, IL-1β was supplemented during
the cell culture of human articular chondrocytes, and the
eﬀects of melatonin on ECM synthesis and degradation were
evaluated. In in vivo experiments, destabilization of the
medial meniscus (DMM) surgery was performed to establish
an OA mouse model, followed by intra-articular injection of
melatonin for up to four weeks. To further investigate the
underlying mechanisms, globe miRNA expression analysis
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was performed and the role of miR-140 in melatoninmediated antiosteoarthritic eﬀects was investigated.

2. Materials and Methods
2.1. Human Cartilage Sampling and Chondrocyte
Preparation. The study protocol for using discarded human
cartilage samples was reviewed and approved by the Ethics
Committee of the First Aﬃliated Hospital of Soochow
University. Cartilage samples were obtained from six OA
patients (3 males and 3 females, age 60:4 ± 11:6) who underwent total joint replacement.
Articular cartilages from the femoral condyle and tibial
plateau were minced into pieces and sequentially digested
with 2 mg/mL type II collagenase (Thermo Fisher Scientiﬁc,
Waltham, MA, USA) at 37°C overnight. Undigested tissue
remnants were removed using a 100 μm nylon mesh (BD
Biosciences, San Jose, CA, USA). The isolated chondrocytes
were seeded into 175 cm2 culture ﬂasks (Costar, Tewksbury,
MA, USA) and cultured in Dulbecco’s modiﬁed Eagle’s
medium: nutrient mixture F-12 (DMEM/F-12) containing
10% fetal bovine serum (FBS, Thermo Fisher Scientiﬁc),
penicillin (100 U/mL), and streptomycin (100 μg/mL) at
37°C in an atmosphere of 5% CO2. Primary chondrocytes
were trypsinized by 0.25% trypsin-EDTA (trypsin-ethylenediaminetetraacetic acid; Thermo Fisher Scientiﬁc) and
replated. Chondrocytes at passage one were used for subsequent experiments.
2.2. In Vitro Culture of Human Chondrocytes and
Treatments with IL-1β and Melatonin
2.2.1. Chondrocyte Treatment. Cultured chondrocytes were
maintained as a monolayer in DMEM/F12 with 10% FBS at
37°C. To establish an in vitro arthritic microenvironment,
recombinant IL-1β at 5 ng/mL (Peprotech, Rocky Hill, NJ,
USA) was supplemented in the medium for the indicated
periods of time. Melatonin (Sigma-Aldrich, St. Louis, MO,
USA) was dissolved in absolute ethanol (EtOH) at a stock
concentration of 250 mM and then diluted in a complete
medium at a concentration of 1 μM or 100 μM. Cells in the
vehicle group were treated with an equal volume of EtOH
(0.4 μL per mL medium).
2.2.2. Transfection of miR-140 Antagomir. miRNA-140
antagomir (antago miR-140) and negative control (antago
miR-NC) oligonucleotides were obtained from GenePharma
Co., Ltd. (Shanghai, China). The sequence of antago miR-140
is 5 ′ -CUCCCUUCUCUUCUCCCGUCUU-3 ′ and NC is
5 ′ -CUCCCUUCUCUUCUCCCGUCUU-3 ′ . Chondrocytes
were seeded in 6-well plates and transfected with miR140 antagomir (100 nM) or NC miRNA using Lipofectamine 2000 (Thermo Fisher Scientiﬁc) according to the
manufacturer’s protocol. Forty-eight hours after transfection, the cells were treated with 5 ng/mL of IL-1β in the
presence or absence of melatonin.
2.2.3. Cell Proliferation. The detailed procedures are provided
in the Supplementary data (available here).
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2.2.4. Quantitative Real-Time Polymerase Chain Reaction
(PCR) Analysis. Total RNA was extracted using the TRIzol®
reagent (Thermo Fisher Scientiﬁc) according to the manufacturer’s protocol. Complementary DNA (cDNA) was synthesized from 1 μg of total RNA using the RevertAid First Strand
cDNA Synthesis Kit (Thermo Fisher Scientiﬁc), and realtime PCR was performed with the iTap™ Universal SYBR®
Green Supermix kit (Bio-Rad, Hercules, CA, USA) on a
CFX96™ Real-Time PCR System (Bio-Rad). Transcript levels
of COL2A1 (type II collagen), ACAN (aggrecan), SOX9
(SRY-box-containing gene 9), ADAMTS4, ADAMTS5,
MMP9, and MMP13 were evaluated with GAPDH (glyceraldehyde-3-phosphate dehydrogenase) as an internal standard.
Relative transcript levels of target genes were calculated using
the comparative Ct (2−ΔΔCt) method. The primer sequences
used in this study are listed in Supplementary Table 1.
2.2.5. Immunoﬂuorescence. The detailed procedures are provided in the Supplementary data.
2.2.6. Western Blotting. The detailed procedures are provided
in the Supplementary data.
2.3. In Vivo Experiments
2.3.1. Mouse Model of Surgically Induced OA. Animal experiments were performed according to the Guidelines for Animal Experimentation of Soochow University and with the
approval of the Ethics Committee of the First Aﬃliated Hospital of Soochow University. Male, nine-week-old C57BL/6J
mice were purchased from the Animal Center of Soochow
University. To establish the mouse model of OA, DMM surgery was performed to induce mild instability of the knee
according to a previous study [15]. Brieﬂy, mice were anesthetized using an inhalation anesthesia system (chamber
ﬁlled with 2.0% isoﬂurane plus 30% oxygen, RWD Life Science, Shenzhen, China). The medial meniscotibial ligaments
(MML) in the right knees were transected using microsurgical scissors to cause the instability of the medial meniscus. As
controls, sham surgery was performed in the left knees, in
which the capsular incision was made but the MML was left
intact. All surgeries were performed by the same person (ZY).
2.3.2. Intra-Articular Injection of Melatonin and the miRNA140 Antagomir. Melatonin was dissolved in absolute ethanol
and diluted in saline (0.9% NaCl) to yield a ﬁnal concentration of 10 mg/mL. After surgery, the sham-op and DMM-op
mice were treated with equal amounts (10 μL) of melatonin
or saline via intra-articular injection through the patellar
tendon. The mice were injected twice a week for four weeks,
then euthanized to collect samples of their medial femoral
condyle cartilage. For miR-140 inhibition experiments,
DMM-op mice were treated with equal amounts (10 μL) of
miRNA control (NC) or miR-140 antagomir (250 nM) via
intra-articular injection on days 3 and 7 postsurgery along
with melatonin administration.
2.3.3. Histology and Immunohistochemistry. Dissected mouse
knees were ﬁxed in 10% formalin and decalciﬁed in 10%
EDTA (pH = 7:4, Sigma-Aldrich) for 2 weeks. After decalci-
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ﬁcation, each specimen was embedded in paraﬃn and sagittally sectioned at a thickness of 6 μm. For histological
analysis, the sections were stained with hematoxylin and
eosin (H&E) and Safranin O (S.O.)/Fast Green (SigmaAldrich). Histological images were taken with a bright-ﬁeld
microscope (Zeiss Axiovert 200, Oberkochen, Germany).
The slides stained with Safranin O/Fast Green were scored
by three independent investigators (ZY, LT, and HF) blinded
to group assignment, using the Osteoarthritis Research Society International (OARSI) scoring system [16].
For immunohistochemistry, the paraﬃn-embedded sections were dewaxed using xylene and hydrated in decreasing
graded ethanol solutions. The slides were incubated with 1%
hydrogen peroxide (H2O2; Sigma-Aldrich) for 30 min and
then treated with 2 mg/mL testicular hyaluronidase (SigmaAldrich) for 30 min at 37°C. The slides were blocked in
1.5% goat serum, followed by incubation with speciﬁc antiCollagen II (COL II; ab34712) or anti-Collagen I (COL I;
ab34710, Abcam) primary antibodies overnight at 4°C. A
secondary antibody of biotinylated goat anti-rabbit (Vector
Laboratories, Burlingame, CA, USA) was applied for 30 min,
after which avidin-biotin complex ampliﬁcation (Vectastain
ABC kit, Vector Laboratories) was used. Finally, immunohistochemistry was detected using 3,3 ′ -diaminobenzidine
(DAB; Vector Laboratories) as a substrate, and counterstaining was performed with hematoxylin. The percentage of
COL II- or COL I-positive cells was counted (per 100 μm2
area in each section) for quantitative evaluation.
2.4. Microarray. The detailed procedures are provided in the
Supplementary data.
2.5. miRNA Expression Analysis. The detailed procedures are
provided in the Supplementary data.
2.6. Statistical Analysis. All statistical analyses were performed using the SPSS 13.0 statistical software (SPSS Inc.,
Chicago, IL, USA). Data points are presented as means ±
standard error of mean (S.E.M.) for at least three independent experiments. Statistical signiﬁcance was determined
using the two-tailed Student’s t-test for comparisons between
two groups and one-way Analysis of Variance (ANOVA)
with Tukey’s post hoc test for multiple group comparisons.
p < 0:05 (∗) was considered statistically signiﬁcant and
p < 0:01 (∗∗) was considered highly signiﬁcant.

3. Results
3.1. The Eﬀect of Melatonin on Human Chondrocytes under
Normal Culture Conditions. Human articular chondrocytes
were treated with melatonin at 1 μM and 100 μM concentrations. The CCK-8 results showed that treatment with 100 μM
melatonin improved cell proliferation by 11.4% on day 5 and
24.5% on day 7 (Figure 1(a)). Furthermore, melatonin treatments signiﬁcantly upregulated transcript levels of COL2A1
by 24.0% at 1 μM and 34.2% at 100 μM (Figure 1(b)). Similarly, gene expressions of ACAN (Figure 1(c)) and SOX9
(Figure 1(d)) were both enhanced by melatonin treatments.
The immunoﬂuorescence experiment conﬁrmed the protein
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Figure 1: The eﬀect of melatonin on cell proliferation and matrix synthesis in human articular chondrocytes. (a) Chondrocytes were treated
with melatonin (MT) at concentrations of 1 μM and 100 μM, and cell proliferation was evaluated using the CCK-8 assay. Untreated cells
served as the control group (CTRL) and cells treated with ethanol (EtOH) served as the vehicle group. (b–d) The mRNA levels of
chondrogenic genes, including COL2A1 (b), ACAN (c), and SOX9 (d), were quantiﬁed with real-time PCR using GAPDH for
normalization. (e) The protein expression of type II collagen was conﬁrmed through immunoﬂuorescence. Scale bar = 50 μm. Values are
the mean ± S:E:M: of six independent experiments (n = 6) in cell proliferation assays and four independent experiments (n = 4) in PCR
experiments. Statistically signiﬁcant diﬀerences are indicated by ∗ where p < 0:05 or ∗∗ where p < 0:01 between the indicated groups.

expression of Collagen II in the control and melatonintreated chondrocytes (Figure 1(e)).
3.2. The Eﬀect of Melatonin on Matrix Synthesis in IL-1βStimulated OA Chondrocytes. To investigate the protective

eﬀect of melatonin on OA chondrocytes, we ﬁrst established
an in vitro OA environment by adding 5 ng/mL of IL-1β during cell culturing. The CCK-8 assay showed that cell proliferation was reduced by 19.6% in the presence of IL-1β, whereas
melatonin treatment (100 μM) signiﬁcantly increased cell
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proliferation by 15.4% compared with the IL-1β group
(Figure 2(a)). Real-time PCR data suggested that, in IL-1βstimulated chondrocytes, transcript levels of COL2A1 were
downregulated by 56.6%. Treatment with 100 μM melatonin
signiﬁcantly upregulated the gene expression of COL2A1 by
36.3% compared with the IL-1β group, but the level was still
40.8% lower than that of the control group (Figure 2(b)).
Consistently, the high concentration of melatonin increased
the transcript levels of ACAN by 51.4% (Figure 2(c)) and
SOX9 by 52.1% (Figure 2(d)) compared to the IL-1β-treated
chondrocytes. The immunoﬂuorescence staining showed
that the synthesis of Collagen II in chondrocytes was suppressed by IL-1β treatment but restored by melatonin supplementation (Figure 2(e)). Western blot data conﬁrmed
that protein levels of cartilage ECM, such as Collagen II
and aggrecan, were signiﬁcantly increased by 100 μM of melatonin (Figure 2(f) and Supplementary Figures 1A and 1B).
3.3. Inhibition of IL-1β-Induced Matrix Degradation by
Melatonin in Chondrocytes. We further investigated the eﬀect
of melatonin on IL-1β-induced matrix-degrading enzymes.
MMPs and ADAMTSs are important proteases that can
degrade a wide range of matrix components. Real-time
PCR data showed that IL-1β stimulation resulted in an
87.2% increase in the gene expression of ADAMTS4, whereas
melatonin treatment downregulated its expression in a dosedependent manner (by 24.9% at 1 μM and by 47.8% at
100 μM; Figure 3(a)). Similarly, treatment with 100 μM melatonin signiﬁcantly decreased the transcript levels of
ADAMTS5 by 40.6% (Figure 3(b)), MMP9 by 50.5%
(Figure 3(c)), and MMP13 by 50.7% (Figure 3(d)). The inhibitory eﬀects of melatonin on these matrix-degrading enzymes
at the protein levels were conﬁrmed by Western blot assays
(Figure 3(e) and Supplementary Figures 1C–1F).
3.4. Prevention of DMM-Induced OA in Mice by IntraArticular Injection of Melatonin. To investigate the antiarthritic eﬀects of melatonin, sham-op and DMM-op mice
were treated with melatonin via intra-articular injection. Histological and immunohistochemical analyses conﬁrmed the
loss of proteoglycan and Collagen II in the DMM group,
whereas melatonin treatment prevented DMM-induced cartilage matrix destruction (Figure 4(a)). In particular, the positive staining of Collagen I was observed in the DMM-treated
mice, which is a typical marker for OA development. In contrast, melatonin treatment suppressed the expression of Collagen I. In the melatonin-treated OA mice, the OARSI score
was signiﬁcantly reduced compared to that of the DMM
group (Figure 4(b)). Consistently, the percentage of chondrocytes that stained positively for Collagen II was increased in
the DMM+melatonin group (Figure 4(c)), while the percentage of Collagen I-positive cells was decreased (Figure 4(d)).
These results indicate that intra-articular injection of melatonin successfully attenuated surgically induced OA progression in mice by modulating cartilage matrix homeostasis.
3.5. Melatonin-Mediated Diﬀerential miRNA Expression
Proﬁles in Human Chondrocytes. To identify the diﬀerentially
expressed miRNAs that were regulated by melatonin, micro-
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array analysis was performed. As shown in Figure 5(a), after
72 h of stimulation of chondrocytes with 100 μM melatonin,
the heat map of miRNA expression patterns revealed that a
total of 50 diﬀerentially expressed miRNAs (1.5-fold up- or
downregulated) were identiﬁed (Supplementary Table 2).
Among them, 29 miRNAs were upregulated by melatonintreated cells, including miR-193b-5p (3.00-fold), miR-26b-3p
(2.86-fold), miR-140-5p (2.37-fold), and miR-95-3p (2.27fold). On the other hand, 21 miRNAs were downregulated
by melatonin treatment, including miR-9-5p (5.87-fold),
miR-204-5p (4.05-fold), miR-145-5p (3.23-fold), and miR181a-3p (2.29-fold). Considering the important role of
miR-140 in the pathogenesis of OA, we performed realtime PCR assays to validate the changes of miR-140
expression. IL-1β stimulation resulted in a marked reduction
in the level of miR-140 in human chondrocytes by 49.2%.
Melatonin treatment upregulated the expression of miR-140
by 1.2-fold and 1.5-fold, respectively, compared with the
CTRL and IL-1β groups (Figure 5(b)). To investigate speciﬁc
miRNA-regulated gene pathways involved in the pathology
of OA, pathway enrichment analysis was performed using
DAVID. As shown in Figure 5(c), 27 pathways were
signiﬁcantly enriched, including protein processing in the
endoplasmic reticulum, PPAR signaling pathway, p53
signaling pathway, Notch signaling pathway, and Hedgehog
signaling pathway.
3.6. Reverse of Melatonin-Mediated Antiarthritic Eﬀects by
Inhibition of miR-140. To investigate the role of miR-140 in
melatonin-mediated antiarthritic eﬀects, chondrocytes were
transfected with miR-140 antagomir or an NC miRNA.
Real-time PCR experiments conﬁrmed that miR-140 antagomir transfection resulted in an 87.7% reduction in the level of
miR-140, whereas miR-NC transfection barely aﬀected miR140 expression (Figure 6(a)). Inhibition of miR-140 reversed
the inhibitory eﬀects mediated by melatonin on matrixdegrading enzymes in IL-1β-stimulated chondrocytes. Compared to the IL-1β+MT group, miR-140 antagomir transfection increased the gene expression of ADAMTS4 by 64.0%
(Figure 6(b)), ADAMTS5 by 70.8% (Figure 6(c)), MMP9 by
93.1% (Figure 6(d)), and MMP13 by 1.4-fold (Figure 6(e)).
The protein levels of matrix-degrading enzymes were conﬁrmed by Western blot experiments (Figure 6(f) and Supplementary Figure 2).
We further investigated the eﬀect of intra-articular
injection of miR-140 antagomir on OA progression. After
the DMM surgery, OA mice were injected with miR-140
antagomir along with melatonin. Histology results showed
reduced levels of proteoglycan and Collagen II in the
antagomir-treated mice (Figure 7(a)). Importantly, immunohistochemical analysis revealed strong positive staining
for Collagen I in the antagomir-treated mice. In the
miR-140 antagomir group, the OARSI score was signiﬁcantly increased (Figure 7(b)) and the percentage of Collagen II-positive chondrocytes decreased (Figure 7(c)), in
contrast to the increased percentage of Collagen Ipositive cells (Figure 7(d)). These results suggest that inhibition of miR-140 completely abrogated the antiarthritic
eﬀect of melatonin.
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Figure 2: In vitro treatments with melatonin protected human articular chondrocytes from IL-1β-induced OA environment. (a)
Chondrocytes were exposed to IL-1β (5 ng/mL) and then treated with melatonin (MT) at concentrations of 1 μM and 100 μM. Cell
proliferation was evaluated using the CCK-8 assay. (b–d) The mRNA levels of chondrogenic genes, including COL2A1 (b), ACAN (c), and
SOX9 (d), were quantiﬁed. (e) The protein expression of type II collagen was conﬁrmed by an immunoﬂuorescence experiment. Scale bar
= 50 μm. (f) The protein levels of aggrecan and type II collagen in melatonin-treated cells were determined using Western blot assays.
Values are the mean ± S:E:M: of six independent experiments (n = 6) in cell proliferation assays, four independent experiments (n = 4) in
PCR experiments, and three independent experiments (n = 3) in Western blot assays. Statistically signiﬁcant diﬀerences are indicated by #
where p < 0:05 or ## where p < 0:01 vs. the CTRL group and ∗ where p < 0:05 or ∗∗ where p < 0:01 between the indicated groups.

4. Discussion
The imbalance between the anabolism and catabolism of the
cartilage matrix is the hallmark of OA, which is induced by
the increased number of proinﬂammatory cytokines. IL-1β
is an important mediator of joint inﬂammation; not only
does it blunt the synthesis of cartilage ECM, it also stimulates
the expression of matrix-degrading enzymes. It was reported
that IL-1β inhibited chondrogenesis of human MSCs
through activation of the nuclear factor κ-light-chain
enhancer of activated B cell (NF-κB) signaling pathway
[17]. In this study, we used IL-1β to mimic the OA inﬂammatory environment in vitro and showed that IL-1β stimulation signiﬁcantly suppressed the synthesis of cartilagespeciﬁc ECM (e.g., Collagen II and aggrecan). However,
treatment with melatonin promoted the expression of cartilage ECM at both the mRNA and protein levels, even in the
presence of IL-1β. SOX9 plays an important role in chondrogenesis by regulating matrix protein synthesis during neocartilage formation [18]. Consistent with previous studies, we
found that melatonin signiﬁcantly increased the level of transcriptional factor SOX9 even in IL-1β-treated chondrocytes.
In addition, chondrocyte proliferation was improved by melatonin treatments in a dose-dependent manner, in which
SOX9 may contribute to an increased number of proliferating chondrocytes [19].
On the other hand, melatonin was demonstrated to have
an inhibitory eﬀect on cartilage ECM degradation. In this
study, we demonstrated that, in IL-1β-stimulated chondrocytes, melatonin treatments led to a signiﬁcant reduction in
the expression of matrix-degrading enzymes such as
ADAMTS4 and ADAMTS5. These two proteinases are
responsible for aggrecan degradation during OA development, which are found at increased mRNA expression and
protein levels in OA cartilage [20]. Knockout of ADAMTS4
and ADAMTS5 in mice protected the hyaline cartilage
against proteoglycan degradation and decreased the severity
of murine OA [21]. Inhibition of ADAMTS4 and ADAMTS5
by melatonin preserved the intact proteoglycan network in
cartilage ECM, which may further protect the cartilage collagen network (especially Collagen II) from degradation

induced by MMPs during OA progression [22]. In addition,
we showed that melatonin signiﬁcantly decreased MMP13
levels in IL-1β-induced chondrocytes, which may contribute
to the attenuation of matrix loss in OA cartilage. However,
the regulatory eﬀect of melatonin on MMP13 is still disputable. Hong et al. suggested that melatonin promotes ECM
remodeling in OA cartilage through the upregulation of
MMP13 [23]. The diﬀerent eﬀects of melatonin on MMP13
may be due to the low dosage of melatonin and the complex
interventions involved, which combined treadmill exercise
with melatonin treatments of only up to 1 μM.
In addition to the transcriptional regulations, the present
study is the ﬁrst to demonstrate that melatonin prevents OAinduced cartilage destruction by regulating the expression of
matrix-degrading enzymes at the posttranscriptional level.
Previous studies have reported that several miRNAs are
involved in the pathogenesis of OA, such as miR-9, miR27b, miR-34a, miR-140, and miR-146 [24]; however, the
eﬀects of melatonin on modulating miRNAs in OA chondrocytes have not been reported. In this study, we ﬁrst identiﬁed
miR-140 as a melatonin-responsive miRNA in chondrocytes,
characterized by a signiﬁcant upregulation by melatonin with
or without IL-1β stimulation. miR-140, a cartilage-speciﬁc
miRNA, has been shown to inhibit the NF-κB signaling pathway in IL-1β-treated articular chondrocytes and to reduce
cartilage ECM breakdown via downregulation of ADAMTS5
[25]. The negative eﬀect of miR-140 on MMP9 has been
reported to inhibit breast cancer invasion [26], while estrogen has been shown to suppress MMP13 expression through
the upregulation of miR-140 in the development of menopausal arthritis [27]. In addition, the microarray results in
this study demonstrated that melatonin modulated the
expression of several miRNAs involved in cartilage development and OA progression. For example, we observed that
melatonin treatment upregulated the expression of miR-95
and downregulated the expression of miR-9 and miR-204.
miR-95 has been reported to promote cartilage matrix
expression by directly inhibiting histone deacetylase 2/8
(HDAC2/8) [28]. Previous studies have demonstrated that
miR-9 [29] and miR-204 [30] markedly increase in OA cartilage and contribute to the disrupted matrix homeostasis via
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Figure 3: In vitro treatments with melatonin inhibited the expression of matrix-degrading enzymes stimulated by IL-1β. (a–d) The mRNA
levels of matrix-degrading enzyme genes, including ADAMTS4 (a), ADAMTS5 (b), MMP9 (c), and MMP13 (d), were quantiﬁed with realtime PCR using GAPDH for normalization. (e) The protein levels of matrix-degrading enzymes in melatonin-treated cells were
determined using Western blot assays. Values are the mean ± S:E:M: of four independent experiments (n = 4) in PCR experiments and
three independent experiments (n = 3) in Western blot assays. Statistically signiﬁcant diﬀerences are indicated by # where p < 0:05 or ##
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upregulation of IL-6 expression and inhibition of the sulfated
proteoglycan biosynthesis pathway, respectively. Therefore,
further studies are necessary to investigate the eﬀects of
melatonin on other OA-related miRNAs and to unravel the
regulation of melatonin-responsive miRNAs on cartilage
matrix homeostasis.
The underlying mechanisms by which melatonin regulates miR-140 expression are not fully understood. The
miR-140 gene was reported to be located in an intronic
region of its host gene, the WW domain-containing E3 ubiquitin protein ligase 2 (WWP2) [31]. Yang et al. conﬁrmed
that miR-140 was cotranscribed with the C-terminal isoform
of WWP2 and was directly induced by SOX9 via binding to
the WWP2 gene. miR-140 was crucial for chondrocyte proliferation through its targeting of Sp1, which is the activator

of p15INK4b. This was because the inhibition of miR-140
resulted in the arrest of proliferation in micromass cultures
[32]. In addition, Tardif et al. demonstrated that regulation
of miR-140 expression can be independent of WWP2. In
normal chondrocytes, mechanotransduction signals induced
the translocation of the nuclear factor of activated T-cells 3
(NFAT3) to the nucleus and subsequently activated the
expression of miR-140, whereas in OA chondrocytes, overexpression of transforming growth factor-β (TGF-β) resulted
in the phosphorylation of mothers against decapentaplegic
homolog 3 (SMAD3) that directly inhibited miR-140 [33].
Moreover, a previous study reported that in OA chondrocytes, the increased levels of miR-145 directly inhibited miR140 expression, resulting in a reduction in cartilage ECM gene
expression and an increase in the ECM-degrading enzyme
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expressed miRNAs in chondrocytes in response to melatonin were illustrated as a heat map. The color bars on the left of the heat map
indicate gene expression level; red denotes high expression and blue denotes low expression, relative to the median. (b) Real-time PCR
validation of miR-140 expression in IL-1β-treated and melatonin-treated chondrocytes. Values are the mean ± S:E:M: of four independent
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MMP13 [34]. In this study, we found that melatonin suppressed the expression of miR-145 in human chondrocytes,
suggesting that the attenuation of OA progression by melatonin may involve other miRNAs. Therefore, the
melatonin-mediated regulation of cartilage ECM synthesis
and degradation at the posttranscriptional level will be an
important area for future investigation. Furthermore, based
on the pathway enrichment analysis, we found that several
miRNA-regulated gene pathways were involved in the
melatonin-mediated antiarthritic eﬀects, such as the PPAR,

p53, and Notch signaling pathways. For example, the Notch
signaling pathway regulates cell diﬀerentiation and apoptosis through a single-pass transmembrane cell surface receptor [35] and has been reported to play an important role in
articular cartilage degradation and OA development [36]. Li
et al. showed that treatment with melatonin activated the
Notch signaling pathway and increased the proliferation
and diﬀerentiation of neural stem cells via downregulation
of miR-363 [37]. However, the underlying mechanisms
of melatonin-mediated signaling pathways including the
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Figure 6: Inhibition of miR-140 intensiﬁed IL-1β-induced matrix degradation in human chondrocytes. Chondrocytes were treated with
5 ng/mL IL-1β and 100 μM melatonin (MT). To inhibit miR-140 expression, chondrocytes were transfected with miRNA-140 antagomir
(antago miR-140), and cells that were transfected with negative control miRNA (antago miR-NC) served as a control. (a) The expression
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Figure 7: Inhibition of miR-140 counteracted the antiarthritic eﬀects of melatonin in surgically induced OA mice. After the destabilization of
the medial meniscus (DMM) surgery, the sham-op and DMM-op mice were injected with melatonin (MT), negative control miRNA (antago
miR-NC), or miRNA-140 antagomir (antago miR-140). (a) Representative images of histological (H&E and Safranin O/Fast Green) and
immunohistochemical (COL II and COL I) staining of the medial femoral condyle in OA mice. Scale bar = 100 μm. (b) OARSI scores were
calculated based on the Safranin O/Fast Green staining results. (c, d) The percentages of COL II-positive (c) or COL I-positive (d)
chondrocytes were counted. In each section, the quantitative analyses were counted at three random regions and then averaged. Values
are the mean ± S:E:M: of ten independent experiments (n = 10). Statistically signiﬁcant diﬀerences are indicated by ## where p < 0:01 vs.
the CTRL group and ∗∗ where p < 0:01 between the indicated groups.

Notch in OA chondrocytes will be investigated in our
future studies.
The delivery of melatonin in animal studies is traditionally through oral administration or intraperitoneal injection.
Daily oral administration of melatonin (100 mg/kg body
weight/day) has been reported to prevent ovariectomyinduced bone degeneration by increasing bone formation in
mice [38], while intraperitoneal melatonin injections were
proven to eﬀectively alleviate titanium particle-induced
inﬂammatory osteolysis in a murine calvarial model [39].
However, considering that chondrocytes uptake nutrients
mainly from the synovial ﬂuid, intra-articular injection is an
eﬀective way to administer melatonin into the articular cavity
in DMM-induced OA mice. Intra-articular injection of melatonin successfully ameliorated OA progression by preserving
cartilage ECM homeostasis through miR-140. The preventive
eﬀects of melatonin on OA were conﬁrmed by suppressing
miR-140-mediated ECM destruction, since inhibition of
miR-140 by the antagomir transfection completely neutralized the antiarthritic eﬀects of melatonin in DMM-operated
mice. In agreement with our results, Si et al. showed that overexpression of miR-140 by intra-articular injection inhibited
the expression of matrix-degrading enzymes and protected
cartilage from surgically induced OA in a rat model [40].
One limitation of this study is that we investigated the
therapeutic eﬀects of melatonin on the early stage of OA; it
is unknown whether intra-articular injection of melatonin
will show the same protective eﬀects on late-stage or other
types of OA. Lim et al. showed that intra-articular injection
of melatonin protected chondrocytes from oxidative stressinduced cartilage degradation through activation of the silent
information regulator type 1 (SIRT1) signaling pathway [41].
Our future studies will seek to investigate the eﬀects of
melatonin-mediated miR-140 expression on late-stage OA.

5. Conclusions
In summary, we demonstrated that intra-articular injection
of melatonin ameliorated the progression of OA by protecting cartilage from matrix destruction in surgically induced
OA mice. In an in vitro IL-1β-induced arthritic environment,
melatonin treatment enhanced the synthesis of matrix proteins and suppressed the expression of matrix-degrading
enzymes in human articular chondrocytes. Further molecular
experiments identiﬁed miR-140 as a melatonin-responsive
miRNA and revealed that melatonin regulated the expression
of proteinases at the posttranscriptional level by upregulating
miR-140; it was evidenced by the fact that inhibition of miR140 counteracts the antiarthritic eﬀects of melatonin on OAinduced cartilage loss. Future studies are necessary to unveil
the speciﬁc mechanisms by which melatonin modulates
miR-140 expression and to investigate the therapeutic eﬀects
of melatonin on late-stage OA.
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